Intact Mass Analysis of a Therapeutic Lysine Linked Antibody Drug Conjugate

28th Mar 2022

Biologics represent a growing class of pharmaceuticals being developed to target a variety of disease and illness vectors. Antibody Drug Conjugates (ADCs) combine a monoclonal antibody (mAb) with a cytotoxic drug via a linker. This allows the mAb to target a specific cell type or antigen and deliver a potent molecule without affecting surrounding cells. There are currently twelve approved ADCs with a variety of linkage chemistries of varying specificities. Lysine conjugations are non-specifically conjugated meaning that a heterogenous distribution of payload molecules are present on the final ADC. Measurement of DAR during manufacture is important to ensure correct dosing to the patient.

Click download to read more ‘Intact Mass Analysis of a Therapeutic Lysine Linked Antibody Drug Conjugate ‘.

Download resource

Related Content

Mass Spectrometry

ADCs

ADC Analytical Services

Reduced Subunit Analysis of a Cysteine Linked Antibody Drug Conjugate

Downloads

Reduced Subunit Analysis of a Therapeutic Monoclonal Antibody

Native Intact Analysis of a Cysteine Linked Antibody Drug Conjugate

Downloads

Intact Mass Analysis of a Therapeutic Monoclonal Antibody Biosimilar

Downloads

Peptide Digestion Analysis of a Monoclonal Therapeutic Antibody

Downloads

Measurement of ADC Stability in Plasma via Released Payload Quantitation

Downloads

Measurement of ADC Stability in Serum via Subunit DAR Analysis